humans
Conditions
Interventions
This is a randomized, blinded crossover clinical trial consisting of two interventions: 1) capsules containing 6 g of hydrolyzed (processed) jaboticaba peel and seed powder
2) daily probiotic supplementation for eight weeks, followed by the ingestion of capsules containing 6 g of non-hydrolyzed (unprocessed) jaboticaba peel and seed powder. Initially, the sample size was
Sponsors
Universidade Federal do Rio de Janeiro
Universidade Federal do Rio de Janeiro
Eligibility
Age
20 Years to 49 Years
Inclusion criteria
Inclusion criteria: Healthy participants; men and women; body mass index between 18.50 kg/m2 and 24.99 kg/m2 and 30.00 kg/m2 and 34.99 kg/m2; age between 20 and 49 years
Exclusion criteria
Exclusion criteria: Participants who are illiterate; participants who have been on a weight-loss diet in the last three months; participants who report food allergies; participants who report liver and intestinal diseases; participants who report lactose intolerance; smokers; alcoholics; pregnant or breastfeeding women; participants who have difficulty swallowing capsules; recent and/or routine use of medications, supplements, prebiotics, and antibiotics (last three months)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increase in excretion of ellagitannin metabolites (urolithins) after probiotic supplementation for 8 weeks, assessed by urine urolithin concentration analysis using high-performance liquid chromatography | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
BR
Contacts
Public ContactMariana Monteiro
Universidade Federal do Rio de Janeiro
Outcome results
None listed